Side Effect Revealed: Heart risk found in leukemia drug | Science News



Support credible science journalism.

Subscribe to Science News today.


Side Effect Revealed: Heart risk found in leukemia drug

11:14am, July 26, 2006

Since its introduction a few years ago, the cancer drug imatinib has given patients with chronic myelogenous leukemia an unprecedented chance at long-term survival. But studies of the drug in people and mice reveal an unexpected risk of heart failure lurking beneath imatinib's benefits.

A research team led by Thomas Force of Jefferson Medical College in Philadelphia evaluated 10 patients who suffered moderate-to-severe heart failure while taking imatinib, which is marketed as Gleevec by the drug company Novartis. In all 10 patients, none of whom had had previous heart problems, their heart's blood-pumping efficiency decreased after 1 to 14 months on the drug. When the researchers examined heart tissue from two of the patients, they found cell abnormalities characteristic of heart damage.

In a second study, Force's team gave imatinib to healthy mice. After 3 weeks, those mice showed a deterioration in heart contractions, the researchers report in the August Nature Me

This article is available only to subscribing members. Join the Society today or Log in.

Get Science News headlines by e-mail.

More from this issue of Science News

From the Nature Index Paid Content